Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Operating Expenses: 2014-2024

Historic Operating Expenses for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $82.8 million.

  • Cartesian Therapeutics' Operating Expenses rose 19.80% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.6 million, marking a year-over-year decrease of 8.72%. This contributed to the annual value of $82.8 million for FY2024, which is 26.34% down from last year.
  • Cartesian Therapeutics' Operating Expenses amounted to $82.8 million in FY2024, which was down 26.34% from $112.4 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Operating Expenses ranged from a high of $112.4 million in FY2023 and a low of $73.4 million during FY2020.
  • For the 3-year period, Cartesian Therapeutics' Operating Expenses averaged around $97.2 million, with its median value being $96.2 million (2022).
  • Its Operating Expenses has fluctuated over the past 5 years, first rose by 24.16% in 2020, then declined by 26.34% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Operating Expenses (Yearly) stood at $73.4 million in 2020, then grew by 22.14% to $89.7 million in 2021, then rose by 7.32% to $96.2 million in 2022, then rose by 16.81% to $112.4 million in 2023, then fell by 26.34% to $82.8 million in 2024.